Hugo Hool is an Oncology physician. OpenAlex indexes 10 publications with 503 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year20254 paymentsResearch$63,963openpaymentsdata.cms.gov ↗
- IpsenProgram year20251 paymentResearch$19,009openpaymentsdata.cms.gov ↗
- ExelixisProgram year20258 paymentsResearch
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.1%Other antiemetics42.6%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist7%Granisetron hydrochloride100%Part B, office-administered≥18 patients+ 4 more classes in this area
Cardiovascular
43.1%Heparins or heparinoids for topical use43.1%Heparin sodium100%Part B, office-administered≥22 patientsSensory organs
4.3%Corticosteroid4.3%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
Journal of Clinical Oncology
2023 - Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”